The Exon 20 Group, founded in 2017, provides more than 20 services to EGFR exon 20 insertion patients and HER2 exon 20 insertion patients diagnosed in lung cancer or 24 other cancer types. We are working to turn these two rare diagnoses into manageable chronic diseases. This international organization represents more than 50 countries and includes the key stakeholders necessary to drive these insertion mutations toward cure.
- EGFR Exon 20 and ERBB2 / HER2 Exon 20 Patients, Caregivers and Patient Families
- Thoracic Oncologists and Medical Oncologists who treat EGFR exon 20 patients and ERBB2 / HER2 exon 20 patients—more than 300 thus far
- Cancer Biologists, Medicinal Chemists, Molecular Modelers and other scientists comprising our International Research Consortium
- Oncology Nurses/Clinical Research Coordinators
- Health Regulatory Experts
- Payers and Reimbursement Experts
- Pharmaceutical and Biotech Companies that have EGFR exon 20 drugs and/or ERBB2 / HER2 exon 20 drugs in the standard arsenal or in clinical trials
- Laboratory Medicine (including Anatomic Pathology, Next-Generation Sequencing, and Immune-Cell Studies)
